Objective: Aprotinin has been widely used to reduce bleeding and transfusion requirements in cardiac surgery and in lung transplantation. A recent study found a significant reduction in severe (grade III) primary graft dysfunction (PGD) in lung transplantation where aprotinin had been used. However, recently, concerns regarding the safety of aprotinin have been raised, and the future use of aprotinin is uncertain. In our institution, aprotinin has been widely used in cardiac surgery and transplantation. We decided to review our lung transplant caseload to investigate the impact of aprotinin on PGD and mortality and to guide our future clinical use of this antifibrinolytic. Methods: A retrospective review of prospectively collected data on 213 consecutive patients who underwent single-or double-lung transplantation was performed. Ninetynine patients, who received aprotinin, were compared with 114 patients who did not. The main outcome variables analysed were development of primary graft dysfunction, renal impairment and mortality. Results: Aprotinin was associated with a significantly increased risk of PGD in the first 48 h postoperatively ( p = 0.01). Conclusions: In conclusion, although the benefits of aprotinin on blood loss are well established, this study does not provide support for the use of aprotinin to reduce PGD in lung transplantation and indicates that aprotinin may in fact have a detrimental effect. #
Introduction
Aprotinin, a serine protease inhibitor (Trasylol, Bayer Pharmaceuticals Corp, West Haven, Connecticut, USA), is a drug which has been widely used to reduce bleeding and transfusion requirements, particularly in cardiac surgery [1] . Aprotinin has also been shown to reduce bleeding and transfusion requirements in lung transplantation [2, 3] . Aprotinin has a multitude of other actions, mediated through the inflammatory and fibrinolytic cascades, some of which remain poorly understood. Thus, aprotinin has also come to be used in high-risk surgery to reduce inflammatory responses and minimise ischaemia-reperfusion injury. A recent study found a significant reduction in severe (grade III) primary graft dysfunction (PGD) in lung transplantation where aprotinin had been used [4] . This follows substantial evidence in animal models that aprotinin ameliorates ischaemia-reperfusion injury in lung transplantation [5] . However, recently, concerns regarding the safety of aprotinin have been raised, with studies citing increased renal impairment, perioperative stroke, myocardial infarction and mortality in patients receiving aprotinin [6, 7] . The results of the recent BART (Blood Conservation Using Antifibrinolytics in a Randomized Trial) study have shown a non-significant increase in all-cause mortality and a significant increase in risk of death from cardiac cause in the aprotinin group compared with lysine analogues, leading Bayer to suspend marketing of the drug [8] .
In our institution, aprotinin has been widely used in cardiac surgery, transplantation and in our ventricular assist device workload. The use of aprotinin in lung transplantation has been entirely at the discretion of the surgeon, some using it to reduce bleeding in cases perceived as being at higher risk, and others using it almost routinely to ameliorate ischaemia reperfusion injury. Given the current controversy surrounding this drug, we felt it timely to review our own experience in the lung transplant population. We did not investigate blood loss or transfusion rates as this effect of aprotinin is not disputed. The aims of this review were to investigate the impact of aprotinin on mortality, PGD and other morbidity in our cohort of lung transplant patients. If aprotinin was not shown to be effective in reducing PGD in our lung transplant patients, then we felt that we could not justify continuing to use the drug, given the recent evidence suggesting increased mortality with the use of this antifibrinolytic.
Methods
A retrospective review was undertaken of prospectively collected data on 219 patients who underwent single-or double-lung transplantation at our institution between April 2002 and December 2007. Data after this date were not included as the use of aprotinin was severely restricted during 2008 due to concerns about its safety. In six patients, we were unable to confirm whether aprotinin had or had not been given, and they have been excluded from further analysis. Aprotinin was administered following an intravenous test dose as a 2 million kallikrein inhibiting unit (KIU) loading dose followed by an infusion of 500 000 KIU h À1 for the duration of the procedure. If cardiopulmonary bypass (CPB) was used, then an additional 2 million KIU aprotinin was added to the pump prime. The main outcomes analysed were the impact of aprotinin use on primary graft dysfunction at 0, 12, 24 and 48 h; renal impairment (maximal rise in raw creatinine in first postoperative week) and mortality. Donor and recipient demographics are outlined in Table 1 . The last censored date for survival data was 20 May 2009. Institutional Ethics Committee advice was sought and exemption for specific patient consent was waived as this was a retrospective review of unidentifiable patient data.
International Society for Heart Lung Transplantation (ISHLT) definitions of primary graft dysfunction were used [9] . The classification scheme takes into consideration only two clinical parameters, the chest X-ray and the PaO 2 /FiO 2 ratio, dividing the spectrum of PGD into four grades from 0 to 3 (severe PGD). Time zero is defined as within 6 h of lung reperfusion and it is suggested that the first blood gas in the intensive care unit is the ideal time for this determination. A number of specific inclusion/exclusion criteria exist such as patients on extra-corporeal membrane oxygenation (ECMO) being automatically defined as grade 3, and any subject mechanically ventilated with FiO 2 greater than 0.5 on nitric oxide beyond 48 h after transplant being defined as grade 3.
Statistical analysis
Analysis was performed using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). All variables were initially assessed for normality and log-transformed where appropriate. Comparisons between groups were made using chisquare tests for equal proportion, Student's t-tests for normally distributed data and Wilcoxon rank-sum tests, otherwise. Normally distributed variable has been reported as means (standard error) whilst non-parametric variables have been reported as medians (interquartile range). Data included in the univariate analyses are outlined in Table 2 . Multivariate analysis was performed using multiple linear regression for normally distributed outcomes and reported as parameter estimates (standard error) and an R-square statistic to indicate the amount of variation explained. Multivariate analysis for binomial outcomes was performed using logistic regression and reported as odds ratios (95% confidence interval). As PGD can be expressed as four groups with ordinal properties, an ordinal logistic regression was also used. Multivariate analysis for survival time was performed using Cox-proportional hazards regression. Multivariate models were constructed using a stepwise selection technique and validated using a backwards elimination technique. All variables of statistical or practical importance were considered for inclusion into the multivariate models. A two-sided p value of 0.05 was considered to be statistically significant. Longitudinal analysis of PGD grade was performed using ordinal mixed modelling (NL MIXED procedure), fitting main effects for time and aprotinin and an interaction between aprotinin and time. As aprotinin usage was not randomly allocated, to account for potential allocation bias, a propensity score for aprotinin usage was constructed in accordance with Rubins [10] and was then included as a covariate in the longitudinal analysis. The propensity model was constructed using stepwise logistic regression with a relaxed inclusion criteria of p = 0.20 to capture any potential imbalances, with all available predictors included in the selection process. For ease of interpretation, longitudinal results have been presented as the mean PGD grade at each time point.
Results
The impact of aprotinin on all four PGD groups was analysed separately at each time point. PGD was inputted as a dichotomous variable, that is, it was either present or not. Thus, PGD grades 1-3 were grouped together. Aprotinin was significantly associated with an increased risk of PGD at all time points on univariate analysis. Multivariate analysis was performed to further validate this relationship with results indicating that aprotinin remained a significant factor associated with increased risk of PGD at all time points (Table 2 ). This effect was independent of CPB, which itself was also a significant factor in the first 24 h. Over the time span of this patient cohort, three different preservation solutions have been used in our patients (Euro-Collins, Papworth and Perfadex). As Perfadex solution is now the worldwide standard, we decided to repeat our analysis including only these patients. In that multivariate analysis, the use of aprotinin was again a significant factor at 24 and 48 h ( Table 3) .
As PGD grade 3 is clinically much more significant than the lesser grades of PGD, we also analysed the impact of aprotinin on the different PGD grades separated out. Analysis by the Cochran-Mantel-Haenszel statistic showed an association of aprotinin use with increasing PGD grade at all time points (0 h, p = 0.02; 12 h, p = 0.05; 24 h, p = 0.03; and 48 h, p = 0.02). When analysed longitudinally, there was a significant overall effect for aprotinin usage both before Table 2 Multivariate analysis for PGD -entire cohort (n = 213).
Significant variables
Odds and after adjustment for aprotinin propensity score ( p = 0.01), with those receiving aprotinin having a mean PGD grade that was consistently higher by about one-third of a grade across the range of time points (Fig. 1) . The ratio of creatinine increase was used as a marker of renal function and was found to be well approximated by a lognormal distribution. Univariate analysis showed a significant rise in postoperative creatinine in those patients who received aprotinin (ratio (95% CI) 1.26 (1.13-1.42); p = 0.0001). However, after multivariate analysis, aprotinin was no longer a significant factor ( Table 4 ). The number of patients who required haemodialysis was too small for meaningful analysis.
There were no cerebrovascular events in this patient cohort and so the impact of aprotinin on cerebral injury was not assessed. Other outcomes such as postoperative mechanical ventilation time, length of hospital stay, requirement for postoperative ECMO and 30-day mortality were all significantly worse in the aprotinin group (Table 5) .
Whilst univariate analysis of aprotinin showed a significant association with worse survival (ratio (95% CI) 1.62 (1.04-2.51); p = 0.03), this significance did not remain in the multivariate analysis. The factors significantly associated with time to death by multivariate analysis were the use of Papworth solution for donor organ preservation (ratio 2.46 (1.53-3.95); p = 0.0002), a PGD grade of 3 at 12 h postoperatively (ratio 2.19 (1.32-3.64); p = 0.002) and donor age (ratio 1.02 (1.01-1.04); p = 0.003).
Discussion
The incidence of severe PGD in lung transplantation is reported to be as high as 22% with early mortality in these patients of up to 40-60% [9, 11, 12] . PGD essentially occurs as a result of ischaemia-reperfusion injury, which causes endothelial and alveolar damage leading to pulmonary oedema. PGD has also been found to be an independent predictor for the development and progression of bronchiolitis obliterans [13] . Efforts to ameliorate this injury have involved modifications to preservation solutions, surgical techniques and pharmacological agents in both the preservation solution and the recipient.
Although the findings of this clinical study do not support a role for aprotinin in attenuation of PGD in lung transplantation, there has been substantial experimental work indicating that aprotinin does protect against PGD in both lungs and hearts. Aprotinin has been shown to be beneficial in a number of studies studying its effect on lung PGD in animal models. It has been incorporated into the Euro-Collins flush solution and shown to improve arterial oxygenation in an isolated lung model after 18 h of cold storage [5] , and after 6 and 12 h cold storage [14] . It has also been shown to improve lung compliance, decrease capillary permeability [14] and reduce peak airway pressure after reperfusion [15] . Interestingly, investigation of the impact of adding aprotinin to newer preservation solutions has shown no improvement over Perfadex alone and a significant deterioration in post-ischaemic lung performance when used with Celsior [16] . This seems to be more relevant to our results where we have, in fact, noted a detrimental effect of aprotinin. Because of the time scan captured by our review, three different types of preservation solution have been used (Euro-Collins, Papworth and Perfadex). In our analysis, the type of solution did not have an impact on PGD incidence. As Perfadex is now the worldwide standard in lung protection, we reanalysed our data including only those patients in whom Perfadex had been used (even though our multivariate analysis would have accounted for these variations in preservation solution). In that analysis, aprotinin was still associated with a significantly increased incidence of PGD at 24 and 48 h.
Studies using animal models have attempted to investigate the mechanism by which aprotinin appears to exert its purported protective effect. Lung tissue homogenates, after aprotinin-enhanced preservation and ischaemia reperfusion, have shown significant reductions in malondialdehyde (MDA), a final product of lipid peroxidation [17] and interleukin 8 (IL-8) [15] . Examination of broncho-alveolar lavage fluid has shown significantly lower neutrophil percentage [17] and reduced activation of NADPH oxidase in alveolar macrophages [15] in the aprotinin groups. Despite all of this experimental work, only two groups have previously published their clinical results regarding the impact of aprotinin on lung transplantation [3, 4] . The study by Bittner et al. found a significant reduction in severe (grade III) PGD in lung transplantation where aprotinin had been used. This is in stark contrast to our study results where we have found an increased incidence of PGD in patients in whom aprotinin was used. In Bittner's study, the results of 112 lung transplants performed over 1997-2000 in two centres were compared to 59 lung transplants performed over 2000-2005 where aprotinin was used. Thus, the two groups are not immediately historically comparable. By contrast, our study is a slightly larger cohort of prospectively collected data on contemporaneous patient groups. Bittner's study reports very little detail of the statistical analysis or even the results of multivariate analysis, which makes it a little more difficult to compare their results directly with ours. Their patient cohort is also quite different to ours with their double lung transplant rate about half as much as ours (36% in the control group and 42% in the aprotinin group) and their use of CPB in the aprotinin group is about a third of ours.
The other study report results in a cohort almost exactly the same size as ours (n = 215) [3] . All patients in that study had off-pump bilateral sequential lung transplantation. They were unable to show any difference in transfusion rates (their primary outcome), or in P/F ratio, which they used as a surrogate for PGD (their secondary outcome).
As our study was also retrospective and not randomized, it is possible that there is a selection bias by the surgeon at the time of choosing to use aprotinin for a specific case, although we have endeavoured to control for this bias using a propensity analysis. Whilst this analysis should account for these confounding factors, it is difficult to identify all of the factors that go into a surgeon's decision making at the time of surgery. It is possible that our surgeons are in fact able to identify high-risk patients, which may not be immediately obvious on paper. The fact that significantly more patients in the aprotinin group required CPB for surgery indicates that these were, in fact, a more complex/ill group of patients. However, even taking CPB into account in the multivariate analysis, aprotinin still exerted a significant influence of PGD outcomes.
Although aprotinin was found to have a deleterious impact on renal function by univariate analysis in our cohort, this correlation did not remain at a multivariate level. However, multiple other investigators have found aprotinin to be associated with renal impairment [6, 18, 19] .
Unfortunately, we do not document intra-and postoperative bleeding as part of our database. However, the transfusion rates between those patients who did and did not receive aprotinin were also not statistically different, which is in keeping with the results recently reported by Balsara et al. [3] .
Recent evidence has suggested increased mortality with the use of aprotinin in heart surgery [7, 8] . Although we did not demonstrate any significant survival difference in our aprotinin group on multivariate analysis (aprotinin was associated with increased mortality on univariate analysis), our study population was much smaller than the recently reported Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) [8] . Concerns about the safety of this drug and our findings of increased PGD in lung transplant patients receiving intraoperative aprotinin would contradict the use of this drug in lung transplantation.
This study is limited by its retrospective nature and the non-randomised way in which aprotinin was administered. However, it is a single-centre study of a large number of transplant patients, all receiving surgery in the modern era. The surgery and perioperative management has been administered in a standardised fashion by a small group of surgeons, anaesthetists and intensivists minimising differences in approach. Despite these limitations, our analysis reveals a robust association between aprotinin and increased incidence of PGD.
In conclusion, although the benefits of aprotinin on blood loss are well established, this study has shown a detrimental effect of aprotinin on PGD in lung transplantation.
